Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
Validea Detailed Fundamental Analysis - MSTR
Market Updates

Validea Detailed Fundamental Analysis - MSTR

Below is Validea's guru fundamental report for MICROSTRATEGY INC (MSTR). Of the 22 guru strategies we follow, MSTR rates highest using our Quantitative Momentum Investor model based on the published s...

  • May 30, 2025 05:09 AM PDT
  • EODHD
Validea Detailed Fundamental Analysis - NFLX
Market Updates

Validea Detailed Fundamental Analysis - NFLX

Below is Validea's guru fundamental report for NETFLIX INC (NFLX). Of the 22 guru strategies we follow, NFLX rates highest using our Twin Momentum Investor model based on the published strategy of Das...

  • May 30, 2025 05:09 AM PDT
  • EODHD
Dividend Roundup: Nvidia, Merck, Lockheed Martin, Meta Platforms, and more
Market Updates

Dividend Roundup: Nvidia, Merck, Lockheed Martin, Meta Platforms, and more

[Savings concept - Piggy bank on US nickel coins] PM Images This week's dividend activity included increased payouts from BMO Financial (BMO [https://seekingalpha.com/symbol/BMO]) and Royal Bank of Ca...

  • May 30, 2025 05:06 AM PDT
  • EODHD
Tesla Stock Is Dropping. Why It Can’t Spoil a Wonderful May.
Market Updates

Tesla Stock Is Dropping. Why It Can’t Spoil a Wonderful May.

Investors have bid up Tesla share in anticipation of the company’s June robotaxi service launch in Austin, Texas. Continue Reading View Comments

  • May 30, 2025 05:04 AM PDT
  • EODHD
Murchison Minerals announces $2M non-brokered private placement
Market Updates

Murchison Minerals announces $2M non-brokered private placement

* Murchison Minerals (TSXV:MUR:CA [https://seekingalpha.com/symbol/MUR:CA]) on Friday said it intends to raise up to $2M in a non-brokered private placement, with the proceeds directed towards the com...

  • May 30, 2025 05:01 AM PDT
  • EODHD
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
Market Updates

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more a...

  • May 30, 2025 05:00 AM PDT
  • EODHD
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
Market Updates

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimal...

  • May 30, 2025 05:00 AM PDT
  • EODHD
Wells Fargo & Company Announces Full Redemption of the Capital Securities Issued by CoreStates Capital II and CoreStates Capital III
Market Updates

Wells Fargo & Company Announces Full Redemption of the Capital Securities Issued by CoreStates Capital II and CoreStates Capital III

Exterior of a Wells Fargo bank (Photo: Wells Fargo) SAN FRANCISCO, May 30, 2025--(BUSINESS WIRE)--Wells Fargo & Company (NYSE: WFC) and Wells Fargo Bank, National Association (the "Bank") today announ...

  • May 30, 2025 05:00 AM PDT
  • EODHD
AbbVie Partners with Chicago Cubs on
Market Updates

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) anno...

  • May 30, 2025 05:00 AM PDT
  • EODHD
Summit: Phase III Trial Of Ivonescimab Plus Chemotherapy Shows Positive Results In EGFR-Mutant NSCLC
Market Updates

Summit: Phase III Trial Of Ivonescimab Plus Chemotherapy Shows Positive Results In EGFR-Mutant NSCLC

(RTTNews) - Summit Therapeutics Inc. (SMMT) announced Friday positive topline results from the Phase III clinical trial, HARMONi, evaluating ivonescimab plus chemotherapy in patients with EGFR-Mutant...

  • May 30, 2025 04:53 AM PDT
  • EODHD